Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.07T
Market cap1.07T
Price-Earnings ratio
40.22
Price-Earnings ratio40.22
Dividend yield
0.58%
Dividend yield0.58%
Average volume
2.94M
Average volume2.94M
High today
$1,145.43
High today$1,145.43
Low today
$1,111.56
Low today$1,111.56
Open price
$1,127.94
Open price$1,127.94
Volume
906.67K
Volume906.67K
52 Week high
$1,182.73
52 Week high$1,182.73
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 1.07T, Eli Lilly(LLY) trades at $1,138.91. The stock has a price-to-earnings ratio of 40.22 and currently yields dividends of 0.58%.

On 2026-06-25, Eli Lilly(LLY) stock moved within a range of $1,111.56 to $1,145.43. With shares now at $1,138.91, the stock is trading +2.5% above its intraday low and -0.6% below the session's peak.

Trading activity shows a volume of 906.67K, compared to an average daily volume of 2.94M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,182.73 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,182.73 and a low of $623.78.

LLY News

The Motley Fool 34m
An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?

In the eyes of Wall Street, Eli Lilly (LLY +1.73%) continues to cement its lead over the competition in the field of weight-loss and diabetes drugs. After revea...

An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?
Fox Business 44m
Eli Lilly CEO launches Medicare GLP-1 bridge program after working closely with Trump admin - Fox Business

...

Eli Lilly CEO launches Medicare GLP-1 bridge program after working closely with Trump admin - Fox Business
Seeking Alpha 4h
ProQR prices $50M stock offering; secures $9.2M investment from Eli Lilly

ProQR Therapeutics (PRQR) has priced a registered direct offering of 27.6M ordinary shares at $1.81 per share, expecting to raise about $50M in gross proceeds b...

ProQR prices $50M stock offering; secures $9.2M investment from Eli Lilly

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

TipRanks 6h
Eli Lilly price target raised to $1,232 from $1,119 at Leerink

Leerink analyst David Risinger raised the firm’s price target on Eli Lilly (LLY) to $1,232 from $1,119 and keeps an Outperform rating on the shares. Unlock pow...

Benzinga 8h
Nancy Pelosi Stock Tracker Flags Eli Lilly, Nokia After Trump Praise: ‘Keep An Eye On These Two’

‘Keep An Eye’ Trump said Eli Lilly will invest $3.5 billion in a new pharmaceutical manufacturing facility near Lehigh Valley, a project he said would create m...

Nancy Pelosi Stock Tracker Flags Eli Lilly, Nokia After Trump Praise: ‘Keep An Eye On These Two’
The Motley Fool 10h
The Artificial Intelligence Opportunity Beyond Big Tech: 3 Healthcare Stocks to Watch

Investors looking to capitalize on the rapidly growing artificial intelligence (AI) industry tend to turn toward leading tech corporations. That's understandabl...

The Artificial Intelligence Opportunity Beyond Big Tech: 3 Healthcare Stocks to Watch
TipRanks 23h
Lilly Advances MASLD Pipeline as Early-Stage LY3849891 Study Reaches Completion

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium...

TipRanks 24h
Midday Fly By: Alphabet to replace Verizon in Dow blue-chip index

The major averages were broadly higher as markets rebound from recent losses after a sharp technology-led selloff rattled investors over the last two sessions....

Benzinga 1d
Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact

The partnership expands the relationship between the two companies as they seek to advance novel drug candidates with global potential by combining their respec...

Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact
TipRanks 1d
Controversy Erupts Over Report Trump Has Early Access to Eli Lilly Weight-Loss Drug

A controversy has erupted following a media report that U.S. President Donald Trump has been granted early access to Eli Lilly’s (LLY) newest weight-loss drug b...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.